-
Plenary Session III: Saturday, November 4, 2017
"Partnering With the Community"
Speaker: Drucy Borowitz, M.D. and
Mary B. Dwight
This plenary session will focus on
ways people with CF and their families make a difference by partnering with the
larger community as advocates, by sharing their expertise on living life with
CF with their care center teams, and by supporting with each other through
virtual events and peer mentoring.
-
Plenary Session I: Thursday, October 27, 2016
"A Cure for All: Leaving No One Behind"
Speakers: Mitchell Drumm, Ph.D. and Eric Sorscher, M.D.
This session describes recent advances toward treatment of cystic fibrosis and the pipeline for new and emerging therapies.
-
Plenary Session II: Friday, October 28, 2016
"Clinical Research: A Worldwide CF Community Effort"
Speakers: Christiane De Boeck, M.D., Ph.D. and Patrick Flume, M.D.
The cystic fibrosis clinical trial pipeline is at present very busy -- and this is great news. This session explains how worldwide collaboration and streamlining can optimize the efficiency in the clinical trial arena.
-
Plenary Session III: Saturday, October 29, 2016
"You Can Observe A Lot by Just Watching: Lessons from The CFF Patient Registry"
Speaker: Wayne Morgan, M.D.
This plenary session reviews the role of observational research in improving our understanding of cystic fibrosis, the care of patients with CF, and opportunities to improve this care, highlighting the role of the CF Foundation Patient Registry.
-
Plenary Session I: Thursday, October 8, 2015
"Personalized Medicine"
Speaker: John Paul Clancy, M.D.
This session discusses the concept of personalized medicine in cystic fibrosis, including how therapies are currently personalized and how new medications and tools will allow us to personalize therapy in a precise way.
-
Plenary Session II: Friday, October 9, 2015
"Opening Doors to CF Clinical Research"
Speaker: George Z. Retsch-Bogart, M.D.
This session reviews highlights of clinical research from the past year and looks forward to the large number of new studies ahead. The increased number of studies and potential new therapies will allow even more patients and centers to get engaged in clinical research.